San Diego startup RyboDyn closed a $10 million seed round to fund RyboCypher, a discovery platform that combines deep sequencing of non‑canonical RNAs with proteomics and AI to identify cryptic, tumor‑specific peptides. The company said its CypherAtlas contains data from roughly 1,000 patient tumors and millions of uncharacterized RNAs and peptides; RyboDyn reported in‑vitro tumor killing against at least one cryptic protein target and highlighted a HER2‑negative breast cancer target present in about 45% of tumors in a cohort. Investors framed the funding as backing for a high‑risk, high‑reward hunt for previously hidden therapeutic antigens.